A Randomized, Double-Blind, Placebo-Controlled Repeated Crossover Study to Evaluate the Safety and Tolerability of Intermittent Single Doses of TAK-951 in the Abortive Treatment of Subjects With Cyclic Vomiting Syndrome
Latest Information Update: 07 Feb 2025
Price :
$35 *
At a glance
- Drugs TAK 951 (Primary)
- Indications Familial cyclic vomiting syndrome
- Focus Adverse reactions
- Sponsors Takeda
- 16 Jan 2025 According to ClinicalTrials.gov: US National Institutes of Health, this status of this study is discontinued, due to business reasons prior to first subject dosed.
- 16 Jan 2025 New trial record